The Open Medicinal Chemistry Journal




ISSN: 1874-1045 ― Volume 15, 2021

A Single Amino Acid Substitution Makes WNK4 Susceptible to SB 203580 and SB 202190



Mark Glover1 , Connor Sweeney1, Bill Davis2, Kevin M O’Shaughnessy*, 1
1 Clinical Pharmacology Unit, Department of Medicine, University of Cambridge, Cambridge, UK
2 GlaxoSmithKline Clinical Unit, Addenbrooke’s Hospital, Cambridge, UK

Abstract

Regulation of the SLC12 family of membrane transporters including NCCT involves a scaffold of interacting proteins including the STE 20 kinase SPAK and the WNK kinases, WNK 1 and WNK 4, which are mutated in the hypertensive syndrome of pseudohypoaldosteronism type 2 (PHAII). WNK4 regulates NCCT by affecting forward trafficking to the surface membrane. Studies in Xenopus using kinase dead WNK4 site mutants have produced inconsistent results with regard to the necessity of kinase function for NCCT regulation. Dynamic inhibition of WNK4 by small molecules may bring clarity to this issue however WNK4 is naturally resistant to commercial MAP kinase inhibitors owing to steric constraints prohibiting entry of small molecules to the active site. Using an approach similar to that used in p38 and ERK, we show that a single substitution in WNK4 (T261G) dramatically enhances its susceptibility to the inhibitors SB 202190 and SB 203580.

Keywords: WNK kinases, protein kinase inhibitors, active site, transporters, sequence mutagenesis.


Article Information


Identifiers and Pagination:

Year: 2010
Volume: 4
First Page: 57
Last Page: 61
Publisher Id: TOMCJ-4-57
DOI: 10.2174/1874104501004010057

Article History:

Received Date: 10/4/2010
Revision Received Date: 25/5/2010
Acceptance Date: 25/5/2010
Electronic publication date: 03/09/2010
Collection year: 2010

© Glover et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.


* Address correspondence to this author at the Clinical Pharmacology Unit, Box 110, Addenbrooke’s Hospital, Cambridge, CB2 2QQ, UK; Tel: +44 1223 762578; Fax: +44 1223 762576; E-mail: kmo22@medschl.cam.ac.uk





INTRODUCTION

Protein kinases form a fundamental network of intracellular signalling molecules necessary for most human signal transduction pathways. Abnormal kinase function has been associated with disease processes as diverse as cancer [1Bleeker, F; Felicioni, L; Buttitta, F; Lamba, S; Cardone, L; Rodolfo, M; Scarpa, A; Leenstra, S; Frattini, M; Barbareschi, M; Grammastro, M; Sciarrotta, M; Zanon, C; Marchetti, A; Bardelli, A AKT1E17K in human solid tumours Oncogene, 2008, 27, 5648-5650.], diabetes [2Asano, T; Fujishiro, M; Gabreels, F; Kushiyama, A; Nakatsu, Y; Yonda, M; Kamata, H; Sakoda, H Role of phosphatidylinositol 3-kinase activation on insulin action and its alteration in diabetic conditions Biol. Pharm. Bull, 2007, 30, 1610-1616.], rheumatoid arthritis [3Okuma-Yoshioka, C; Seto, H; Kadono, Y; Atsuhiko, H; Oshima, Y; Kuorosawa, H; Nakamura, K; Tanaka, S Tumor necrosis factor-a inhibits chondrogenic differentiation of synovial fibroblasts through p38 mitogen activating protein kinase pathways Mod. Rheum, 2008, 18, 366-378.] and hypertension [4Cope, G; Golbang, AP; O'Shaughnessy, KM WNK kinases and the control of blood pressure Pharmacol. Ther, 2006, 106, 221-231.]. Recent therapeutic advances using small cell permeable kinase inhibitors have yielded dramatic results; for example the BCR-ABL inhibitor Imatinib, effective in Chronic Myeloid leukaemia [5O'Brien, SG; Guilhot, F; Larson, RA For the IRIS Investigators: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N. Eng. J. Med, 2003, 348, 994-1004.] and the mTOR inhibitor Rapamycin for preventing transplant rejection [6Kahan, B For the Rapamine U.S.Study group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study Lancet, 2000, 356, 194-202.] and have also revolutionised our understanding of signal transduction pathways themselves [7Cuenda, A; Alessi, DR Use of Kinase Inhibitors to Dissect Signalling Pathways Method Mol. Biol, 2001, 99, 161-175.].

Kinases may contribute to hypertension either by augmenting arteriolar vasoconstriction by Rho kinase [8Tawara, S; Shimokawa, H Progress of the study of rho-kinase and future perspective of the inhibitor Yakugku Zasshi, 2007, 127, 501-514.] or by increasing sodium retention in the distal renal tubule through regulation of ENaC by SGK1 [9Xu, B; Stippec, S; Chu, P; Lazrak, A; Li, X; English, J; Ortega, B; Huang, C; Cobb, M WNK1 activates SGK1 to regulate the epithelial sodium channel Proc. Natl. Acad. Sci. USA, 2005, 102, 10315-10320.] and NCCT by WNK kinases [4Cope, G; Golbang, AP; O'Shaughnessy, KM WNK kinases and the control of blood pressure Pharmacol. Ther, 2006, 106, 221-231.]. WNK kinases (With No Lysine Kinases) are a family of four kinases of which the genes for WNK1 and WNK4 are mutated in Gordon syndrome or Pseudohypoaldosteronism type II (PHA II), a rare monogenic form of hypertension. A model in which WNK1 inhibits WNK4 that in turn inhibits NCCT forward trafficking to the apical membrane is well established [4Cope, G; Golbang, AP; O'Shaughnessy, KM WNK kinases and the control of blood pressure Pharmacol. Ther, 2006, 106, 221-231.], although the effect of WNK4 kinase function in regulating NCCT expressed in Xenopus using kinase dead site mutants has yielded inconsistent results [10Wilson, FH; Kahle, KT; Sabath, E; Lalioti, MD; Rapson, AK; Hoover, RS; Hebert, SC; Gamba, G; Lifton, RP Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4 Proc. Natl. Acad. Sci. USA, 2003, 100, 680-684.-12Yang, CL; Zhu, X; Wang, Z; Subramanya, AR; Ellison, DH Mechanisms of WNK1 and WNK4 interaction in the regulation of thiazide-sensitive NaCl cotransport J. Clin. Invest, 2005, 115, 1379-1387.]. A major limitation in the exploration of WNK kinase function in Xenopus as well as in tissues and whole animals has been the absence of specific inhibitors.

The pyridinyl imidazoles SB 203580 and SB 202190 were developed at SmithKline Beecham as inhibitors of IL-1 and TNF production in activated monocytes [13Lee, JC; Young, PR A protein kinase involved in the regulation of inflammatory cytokine biosynthesis Nature, 1994, 372, 739-746.]. Radioligand binding assay subsequently identified the kinase targets now known as the stress activated MAPK kinases, SAPK2a/p38α and SAPK2b/p38β. These SB compounds were used to elucidate some of the physiological effects of this pathway [14Cohen, P The search for physiological substrates of MAP and SAP kinases in mammalian cells Trends Cell. Biol, 1997, 7, 353-361.], as well as identifying downstream targets of the kinases [14Cohen, P The search for physiological substrates of MAP and SAP kinases in mammalian cells Trends Cell. Biol, 1997, 7, 353-361.-16New, L; Jiang, Y; Zhao, M; Liu, K; Zhu, W; Flood, LJ; Kato, Y; Parry, GC; Han, JH PRAK, a novel protein kinase regulated by the p38 MAP kinase EMBO J, 1998, 17, 3384-0.]. X-ray crystallography of SB 203580 bound to p38 kinase revealed the drug binding to the ATP binding pocket and allowed adjacent residues in the pocket to be identified [17Tong, L; Pav, S; White, DM; Rogers, S; Crane, KM; Cywin, CL; Brown, ML; Pargellis, CA A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket Nat. Struct. Biol, 1997, 4, 311-316.]. Threonine106 is located close to the 4-fluorophenyl ring of the inhibitor Fig. (1) and mutation to the more bulky M106 retards kinase inhibition [14Cohen, P The search for physiological substrates of MAP and SAP kinases in mammalian cells Trends Cell. Biol, 1997, 7, 353-361., 17Tong, L; Pav, S; White, DM; Rogers, S; Crane, KM; Cywin, CL; Brown, ML; Pargellis, CA A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket Nat. Struct. Biol, 1997, 4, 311-316., 18Eyres, PA; Craxton, M; Morrice, N; Cohen, P; Goedert, M Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino acid substitution Chem. Biol, 1998, 5, 321-328.]. In fact, a series of T106 p38 mutants showed a hierarchy of kinase inhibition with smaller residues such as glycine or alanine allowing maximum drug binding. Using this approach a previously insensitive kinase, ERK 2, was made drug-sensitive by mutation of the homologous residue Q105 to the smaller T105 [19Fox, E; Coll, JT; Xie, X; Ford, PJ; Germann, UA; Porter, MD; Pazhanisamy, S; Fleming, MA; Galullo, V; Su, MS; Wilson, KP A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase Protein Sci, 1998, 7, 2249-2255.]. Four other closely located residues were also found to modulate ERK2 sensitivity to SB 203580 in a complementary manner.

Fig. (1)

Chemical structure of the p38 kinase inhibitors SB202190 and SB 203580.



We hypothesised that in WNK4, mutation of the homologous amino acid T261 to glycine might facilitate binding of small molecule kinase inhibitors such as the SB compounds to the ATP pocket and so confer drug sensitivity permitting dynamic investigation of WNK4 kinase function on the regulation of NCCT.

MATERIALS AND METH0DOLOGY

Cloning and cRNA Synthesis

Wild type NCCT in ECFP-TNT with cyan fluorescent protein at its N terminal and wild type WNK4 in pcDNA3 were as previously described [11Golbang, AP; Cope, G; Hamad, A; Murthy, M; Liu, C-H; Cuthbert, AW; O'Shaughnessy, KM Regulation of the expression of the Na/Cl cotransporter by WNK4 and WNK1: evidence that accelerated dynamin-dependent endocytosis is not involved Am. J. Physiol. Renal. Physiol, 2006, 291, F1369-F1376.]. The WNK4 cDNA was mutated to T261G using site directed mutagenesis (Stratagene, La Jolla, CA). All sequences were verified using an ABI 377 and Big Dye fluorescent chemistry (Applied Biosystems, Foster City, CA). Copy RNA was transcribed in vitro from linearized plasmids using the T7 mMESSAGE mMACHINE® kit (Ambion, Austin, Tx) and quantified using ultraviolet absorption spectroscopy (Nanodrop, Wilmington, DE).

Expression in Xenopus Oocytes

Xenopus laevis oocytes were harvested and defolliculated as detailed previously [20Golbang, AP; Murthy, M; Hamad, A; Liu, C-H; Cope, G; Van't Hoff, W; Cuthbert, AW; O'Shaughnessy, KM A new kindred with pseudohypoaldosteronism type ii and a novel mutation (564D>H) in the acidic motif of the WNK4 gene Hypertension, 2005, 46, 295-300.]. Briefly, 10 ng of NCCT cRNA was injected in a total volume of 50nl per oocyte, and for coinjections involving WNK4 an additional 10ng cRNA was added to the injectate. RNAase and DNAase free water-injected oocytes were used as controls throughout. Oocytes were then incubated in ND96 containing 2 mM sodium pyruvate, 0.1mg/ml gentamicin and kinase or inhibitors at 18oC for 5 days.

For 22Na+ flux studies, oocytes were placed for 24 hours in Cl- free ND96 solution containing 96mM sodium isethionate, 2mM potassium gluconate, 1.8 mM calcium gluconate, 1mM magnesium gluconate, 5mM HEPES, 2.5mM sodium pyruvate and 5mg/dl gentamicin. Thirty minutes before the addition of uptake medium, oocytes were added to Cl- free ND96 with inhibitors (1mM ouabain, 100µM amiloride and 100µM bumetanide) according to the protocol of Gamba [21Gamba, G; Miyanoshita, A; Lombardi, M; Lytton, J; Lee, WS; Hediger, MA; Hebert, SC Molecular cloning, primary structure and characterization of two members of the mammalian electroneutral sodium-(potassium)-chloride cotransporter family expressed in kidney J. Biol. Chem, 1994, 269, 17713-17722.] . Oocytes were then transferred to isotonic uptake medium (58mM NaCl, 38mM M-methyl-D-glucamine, 2mM KCl, 1.8mM CaCl2 and 5mM HEPES with inhibitors pH 7.4) containing 22Na+ at a final concentration of 2.5µCi/ml and incubated in a gently shaking incubator at 37oC for 1 hour. Oocytes were then washed five times with 3ml ice cold aliquots of isotonic medium and the oocytes counted individually in a gamma counter (Perkin-Elmer Cobra 5003). Thiazide sensitivity was confirmed using 100µM hydrochlorthiazide (data not shown).

Membrane surface expression measurements were performed 5 days after injection by laser-scanning confocal microscopy with a Leica DMRXA confocal microscope. Data was captured using an equatorial section through each oocyte under a x10 objective lens with brightness, contrast and pin-hole settings kept constant for all oocytes in each injection series. The fluorescent signal in the membrane was quantified using Leica confocal software (version 2.61 of LCS Lite®) with sampling made at sixteen equispaced points on the circumference and averaged to give mean total fluorescence intensity in arbitrary fluorescence units (AFUs).

Data Analysis

For all oocyte experiments ten to fifteen oocytes were injected for each cRNA used. Differences between groups were compared by 1-way ANOVA with post hoc testing. Figures show representative experiments that were replicated using at least four different batches of oocytes from different donor animals. The SPSS statistical package (software version 12) was used throughout with significance defined as P < 0.05. The IC50 values for the SB compounds were derived from the fitting of the dose-response curves to a simple logistic function using GraphPad version 4.

RESULTS

T261G Mutant WNK4 Behaves as Wild Type WNK4

22Na+ flux measurable in NCCT injected oocytes was completely inhibited by hydrochlorothiazide (100 μM) as shown in Fig. (2A). Wild type WNK4 coinjection with NCCT decreased 22Na+ uptake by 62% (3.0 +/- 0.1 vs. 7.9 +/- 0.4 nmol/oocyte/h, P<10-4) in keeping with previous reports. T261G WNK4 produced a similar effect reducing 22Na+ uptake through NCCT by 71% (2.3 +/- 0.4 vs. 7.9 +/- 0.4 nmol/ oocyte/h, P< 10-4), which was not significantly different from wild type WNK4 (3.0 +/- 0.1 vs. 2.3 +/- 0.4 nmol/oocyte/h, P> 0.05).

Fig. (2)

The T261G WNK4 mutant behaves like wild type WNK4. A. Oocytes were injected with NCCT wt alone or in combination with WNK4 wt or WNK4 T261G. Mutant WNK4 reduced 22Na+ flux equivalent to the same extent as WNK4 wt. * P< 0.0001vs NCCT alone. B. Confocal microscopy of the fluorescent signal from eCFP-NCCT showed that changes in WNK4 induced 22Na+ flux were accompanied by similar changes in surface membrane expression of the cotransporter. * P< 0.0001 vs NCCT alone.



Confocal microscopy of ECFP-NCCT injected oocytes showed that WNK4 effects on NCCT flux activity were accompanied by parallel changes in surface membrane expression of the transporter Fig. (2B). Wild type WNK4 decreased membrane expression of ECFP-NCCT by 52% (14.1 +/- 1.1 vs. 29.4 +/- 2.6 AFUs, P< 10-4). Similarly T261G WNK4 reduced NCCT surface membrane abundance by 41% (17.2 +/- 1.8 vs. 29.4 +/- 2.6 AFUs, P< 10-4). Again the effects of the two forms of WNK4 kinases were not significantly different from each other (14.1 +/- 1.1 vs. 17.2 +/- 1.8 AFU’s, P >0.05).

Site Mutation of WNK4 Confers Kinase Inhibitor Sensitivity

Xenopus oocytes were injected with cDNA for ECFP-NCCT with either wild type or the mutant WNK4 T261G. They were then incubated with low (0.5 µM) or high (5µM) concentrations of the SB compounds to see if these kinase inhibitors were able to block the catalytic activity of WNK4 and restore 22Na+ uptake. Fig. (3A) shows that 22Na+ uptake by wild type WNK4 injected oocytes was unaffected by incubation with either concentration of the SB inhibitors indicating that the IC50 for both SB compounds must be >5 µM against wild type WNK4. Conversely 22Na+ flux through NCCT coinjected with mutant WNK4 T261G was increased when incubated with either inhibitor; the flux actually returning to the level seen in oocytes injected with NCCT alone.

Fig. (3)

The T261G mutation of WNK4 confers kinase inhibitor sensitivity. A. Oocytes were injected with NCCT wt alone or in combination with either WNK4 wt or WNK4 T261G. The 22Na+ flux assay was then performed with or without 0.5 or 5 µM of each SB compound. * P<0.0001 vs NCCT alone. B. Confocal microscopy of the fluorescent signal from eCFP-NCCT showed that changes WNK4-induced 22Na+ flux were accompanied by parallel changes in surface membrane expression of the cotransporter. * P< 0.05 vs assay without an SB inhibitor.



The changes in 22Na+ flux, were accompanied by parallel changes in the membrane fluorescence and hence membrane expression of NCCT Fig. (3B).

Concentration Response Curves for SB 202190 and SB 203580

These results in Fig. (3) suggested that the IC50 for both SB compounds was at ~100-fold lower for the T261G mutant versus wild type. To confirm this, concentration-response curves were generated for the SB compounds in oocytes expressing WNK4 T216G. The fitted IC50 values were 109 nM for SB 203580 and 147 nM for SB 202190 Fig. (4).

Fig. (4)

Concentration response curves showing reversal of WNK4 T261G inhibition of NCCT 22Na+ flux in Xenopus oocytes by (A) SB 202190 and (B) SB203580. The fitted EC50 values (concentration of inhibitor producing 50% reversal) were respectively 147 and 109 nM.



DISCUSSION AND CONCLUSION

Experiments to study the effects of WNK4 in whole animals and tissues have been hampered by the lack of an inhibitor. Although it is well established that wild type WNK4 inhibits NCCT forward trafficking to the surface membrane [4Cope, G; Golbang, AP; O'Shaughnessy, KM WNK kinases and the control of blood pressure Pharmacol. Ther, 2006, 106, 221-231.], it was unclear whether in tact kinase function was necessary for this to occur. Studies using kinase dead WNK4 site mutants expressed in Xenopus have yielded inconsistent results [10Wilson, FH; Kahle, KT; Sabath, E; Lalioti, MD; Rapson, AK; Hoover, RS; Hebert, SC; Gamba, G; Lifton, RP Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4 Proc. Natl. Acad. Sci. USA, 2003, 100, 680-684.-12Yang, CL; Zhu, X; Wang, Z; Subramanya, AR; Ellison, DH Mechanisms of WNK1 and WNK4 interaction in the regulation of thiazide-sensitive NaCl cotransport J. Clin. Invest, 2005, 115, 1379-1387.].

Within the kinome, the WNKs show closest homology to the MAPKK subgroup of MAPK kinases. Inhibitors of the MAPK kinase family are well described, although the sensitivity of individual kinases is dependent on steric factors around the ATP binding pocket. In keeping with reports using p38 and ERK2 kinases [14Cohen, P The search for physiological substrates of MAP and SAP kinases in mammalian cells Trends Cell. Biol, 1997, 7, 353-361.-16New, L; Jiang, Y; Zhao, M; Liu, K; Zhu, W; Flood, LJ; Kato, Y; Parry, GC; Han, JH PRAK, a novel protein kinase regulated by the p38 MAP kinase EMBO J, 1998, 17, 3384-0., 19Fox, E; Coll, JT; Xie, X; Ford, PJ; Germann, UA; Porter, MD; Pazhanisamy, S; Fleming, MA; Galullo, V; Su, MS; Wilson, KP A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase Protein Sci, 1998, 7, 2249-2255.], we found that mutation of the single threonine residue at position 261of WNK4 (homologous amino acid 106 in p38) to a residue with a much smaller side chain resulted in dramatic enhancement of its sensitivity to SB 202190 and SB203580. The IC50 for both agents shifted from >5000 nM to ~100 nM, so that both inhibitors were able to completely reverse the effect of WNK4 T261G on NCCT in the oocyte system. These results confirm that WNK4 requires a catalytically intact kinase function to affect NCCT trafficking [10Wilson, FH; Kahle, KT; Sabath, E; Lalioti, MD; Rapson, AK; Hoover, RS; Hebert, SC; Gamba, G; Lifton, RP Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4 Proc. Natl. Acad. Sci. USA, 2003, 100, 680-684., 11Golbang, AP; Cope, G; Hamad, A; Murthy, M; Liu, C-H; Cuthbert, AW; O'Shaughnessy, KM Regulation of the expression of the Na/Cl cotransporter by WNK4 and WNK1: evidence that accelerated dynamin-dependent endocytosis is not involved Am. J. Physiol. Renal. Physiol, 2006, 291, F1369-F1376.].

It is hoped that further study of the steric constraints preventing small molecules from gaining access to the active site of WNK kinases may enable the design of compounds capable of inhibiting wild type WNK kinases. The availability of small molecule inhibitors of wild type WNK4 may be attractive therapeutically. Salt-retention through increased expression of NCCT could be useful, for example, in hypotensive states such as autonomic failure. It is not clear that a similar strategy could be used for WNK1. Heterozygous mouse knock-outs for WNK1 do have a lowered blood pressure [22Zabrowicz, BP; Abuin, A; Ramirez-Solis, R; Richter, LJ; Piggott, J; Beltrandelrio, H; Buxton, EC; Edwards, J; Finch, RA; Friddle, CJ; Gupta, A; Hansen, G; Hu, Y; Huang, W; Jaing, C; Key, BW; Kipp, P; Sands, T WNK1 kinase deficiency lowers blood pressure in mice: A gene-trap screen to identify potential targets for therapeutic intervention Proc. Natl. Acad. Sci. USA, 2003, 100, 14109-14114.], but there are contradictory reports of the necessity for intact WNK1 kinase function to influence NCCT via WNK4 [11Golbang, AP; Cope, G; Hamad, A; Murthy, M; Liu, C-H; Cuthbert, AW; O'Shaughnessy, KM Regulation of the expression of the Na/Cl cotransporter by WNK4 and WNK1: evidence that accelerated dynamin-dependent endocytosis is not involved Am. J. Physiol. Renal. Physiol, 2006, 291, F1369-F1376., 12Yang, CL; Zhu, X; Wang, Z; Subramanya, AR; Ellison, DH Mechanisms of WNK1 and WNK4 interaction in the regulation of thiazide-sensitive NaCl cotransport J. Clin. Invest, 2005, 115, 1379-1387.]. WNK1 is also found predominantly in the short form which lacks the kinase domain [23O'Reilly, M; Marshall, E; Speirs, HJ; Brown, RW WNK1, a gene within a novel blood pressure control pathway, tissue-specifically generates radically different isoforms with and without a kinase domain J. Am. Soc. Nephrol, 2003, 14, 2447-2456.], although in states of low potassium diet [24O'Reill, M; Marshall, E; MacGillivray, T; Mittal, M; Xue, W; Kenyon, C J; Brown, RW Dietary electrolyte-driven responses in the renal WNK kinase pathway in vivo J. Am. Soc. Nephrol, 2006, 17, 2402-2413.] or Gordon syndrome, the full length transcript may be physiologically more significant [25Wilson, FH; Disse-Nicodeme, S; Chate, KA; Ishikawa, K; Nelson-Williams, C; Desitter, I; Gunal, M; Milford, DV; Lipkin, GW; Achard, JM; Feeley, MP; Dussol, B; Berland, Y; Unwin, RJ; Mayan, H; Simon, DB; Farfel, Z; Jeunemaitre, X; Lifton, RP Human Hypertension caused by mutations in WNK Kinases Science, 2001, 293, 1107-1112., 26Disse-Nicodeme, S; Desitter, I; Fiquet-Kempf, B; Hout, A; Stern, N; Delagousse, M; Potier, J; Ader, J; Jeunemaitre, X Genetic heterogeneity of famelial hyperkalaemic hypertension J. Hypertens, 2001, 19, 1957-1964.].

In summary, we have shown that T261G mutation of WNK4 renders it susceptible to inhibition by SB202190 and SB203580 and confirming that the ability of WNK4 to regulate NCCT is indeed dependent on kinase activity. This may be useful in elucidating the role of WNK4 kinase activity in regulating renal electrolyte transport experimentally.

GRANTS

MG was supported by a British Heart Foundation (UK) Clinical Studentship FS/06/034 and a Raymond and Beverly Sackler Studentship.

REFERENCES

[1] Bleeker, F; Felicioni, L; Buttitta, F; Lamba, S; Cardone, L; Rodolfo, M; Scarpa, A; Leenstra, S; Frattini, M; Barbareschi, M; Grammastro, M; Sciarrotta, M; Zanon, C; Marchetti, A; Bardelli, A AKT1E17K in human solid tumours Oncogene, 2008, 27, 5648-5650.
[2] Asano, T; Fujishiro, M; Gabreels, F; Kushiyama, A; Nakatsu, Y; Yonda, M; Kamata, H; Sakoda, H Role of phosphatidylinositol 3-kinase activation on insulin action and its alteration in diabetic conditions Biol. Pharm. Bull, 2007, 30, 1610-1616.
[3] Okuma-Yoshioka, C; Seto, H; Kadono, Y; Atsuhiko, H; Oshima, Y; Kuorosawa, H; Nakamura, K; Tanaka, S Tumor necrosis factor-a inhibits chondrogenic differentiation of synovial fibroblasts through p38 mitogen activating protein kinase pathways Mod. Rheum, 2008, 18, 366-378.
[4] Cope, G; Golbang, AP; O'Shaughnessy, KM WNK kinases and the control of blood pressure Pharmacol. Ther, 2006, 106, 221-231.
[5] O'Brien, SG; Guilhot, F; Larson, RA For the IRIS Investigators: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N. Eng. J. Med, 2003, 348, 994-1004.
[6] Kahan, B For the Rapamine U.S.Study group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study Lancet, 2000, 356, 194-202.
[7] Cuenda, A; Alessi, DR Use of Kinase Inhibitors to Dissect Signalling Pathways Method Mol. Biol, 2001, 99, 161-175.
[8] Tawara, S; Shimokawa, H Progress of the study of rho-kinase and future perspective of the inhibitor Yakugku Zasshi, 2007, 127, 501-514.
[9] Xu, B; Stippec, S; Chu, P; Lazrak, A; Li, X; English, J; Ortega, B; Huang, C; Cobb, M WNK1 activates SGK1 to regulate the epithelial sodium channel Proc. Natl. Acad. Sci. USA, 2005, 102, 10315-10320.
[10] Wilson, FH; Kahle, KT; Sabath, E; Lalioti, MD; Rapson, AK; Hoover, RS; Hebert, SC; Gamba, G; Lifton, RP Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4 Proc. Natl. Acad. Sci. USA, 2003, 100, 680-684.
[11] Golbang, AP; Cope, G; Hamad, A; Murthy, M; Liu, C-H; Cuthbert, AW; O'Shaughnessy, KM Regulation of the expression of the Na/Cl cotransporter by WNK4 and WNK1: evidence that accelerated dynamin-dependent endocytosis is not involved Am. J. Physiol. Renal. Physiol, 2006, 291, F1369-F1376.
[12] Yang, CL; Zhu, X; Wang, Z; Subramanya, AR; Ellison, DH Mechanisms of WNK1 and WNK4 interaction in the regulation of thiazide-sensitive NaCl cotransport J. Clin. Invest, 2005, 115, 1379-1387.
[13] Lee, JC; Young, PR A protein kinase involved in the regulation of inflammatory cytokine biosynthesis Nature, 1994, 372, 739-746.
[14] Cohen, P The search for physiological substrates of MAP and SAP kinases in mammalian cells Trends Cell. Biol, 1997, 7, 353-361.
[15] Deak, M; Clifton, AD; Lucocq, JM; Alessi, DR Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may itself mediate activation of CREB EMBO J, 1998, 17, 4426-4441.
[16] New, L; Jiang, Y; Zhao, M; Liu, K; Zhu, W; Flood, LJ; Kato, Y; Parry, GC; Han, JH PRAK, a novel protein kinase regulated by the p38 MAP kinase EMBO J, 1998, 17, 3384-0.
[17] Tong, L; Pav, S; White, DM; Rogers, S; Crane, KM; Cywin, CL; Brown, ML; Pargellis, CA A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket Nat. Struct. Biol, 1997, 4, 311-316.
[18] Eyres, PA; Craxton, M; Morrice, N; Cohen, P; Goedert, M Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino acid substitution Chem. Biol, 1998, 5, 321-328.
[19] Fox, E; Coll, JT; Xie, X; Ford, PJ; Germann, UA; Porter, MD; Pazhanisamy, S; Fleming, MA; Galullo, V; Su, MS; Wilson, KP A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase Protein Sci, 1998, 7, 2249-2255.
[20] Golbang, AP; Murthy, M; Hamad, A; Liu, C-H; Cope, G; Van't Hoff, W; Cuthbert, AW; O'Shaughnessy, KM A new kindred with pseudohypoaldosteronism type ii and a novel mutation (564D>H) in the acidic motif of the WNK4 gene Hypertension, 2005, 46, 295-300.
[21] Gamba, G; Miyanoshita, A; Lombardi, M; Lytton, J; Lee, WS; Hediger, MA; Hebert, SC Molecular cloning, primary structure and characterization of two members of the mammalian electroneutral sodium-(potassium)-chloride cotransporter family expressed in kidney J. Biol. Chem, 1994, 269, 17713-17722.
[22] Zabrowicz, BP; Abuin, A; Ramirez-Solis, R; Richter, LJ; Piggott, J; Beltrandelrio, H; Buxton, EC; Edwards, J; Finch, RA; Friddle, CJ; Gupta, A; Hansen, G; Hu, Y; Huang, W; Jaing, C; Key, BW; Kipp, P; Sands, T WNK1 kinase deficiency lowers blood pressure in mice: A gene-trap screen to identify potential targets for therapeutic intervention Proc. Natl. Acad. Sci. USA, 2003, 100, 14109-14114.
[23] O'Reilly, M; Marshall, E; Speirs, HJ; Brown, RW WNK1, a gene within a novel blood pressure control pathway, tissue-specifically generates radically different isoforms with and without a kinase domain J. Am. Soc. Nephrol, 2003, 14, 2447-2456.
[24] O'Reill, M; Marshall, E; MacGillivray, T; Mittal, M; Xue, W; Kenyon, C J; Brown, RW Dietary electrolyte-driven responses in the renal WNK kinase pathway in vivo J. Am. Soc. Nephrol, 2006, 17, 2402-2413.
[25] Wilson, FH; Disse-Nicodeme, S; Chate, KA; Ishikawa, K; Nelson-Williams, C; Desitter, I; Gunal, M; Milford, DV; Lipkin, GW; Achard, JM; Feeley, MP; Dussol, B; Berland, Y; Unwin, RJ; Mayan, H; Simon, DB; Farfel, Z; Jeunemaitre, X; Lifton, RP Human Hypertension caused by mutations in WNK Kinases Science, 2001, 293, 1107-1112.
[26] Disse-Nicodeme, S; Desitter, I; Fiquet-Kempf, B; Hout, A; Stern, N; Delagousse, M; Potier, J; Ader, J; Jeunemaitre, X Genetic heterogeneity of famelial hyperkalaemic hypertension J. Hypertens, 2001, 19, 1957-1964.
Track Your Manuscript:


Endorsements



"Open access will revolutionize 21st century knowledge work and accelerate the diffusion of ideas and evidence that support just in time learning and the evolution of thinking in a number of disciplines."


Daniel Pesut
(Indiana University School of Nursing, USA)

"It is important that students and researchers from all over the world can have easy access to relevant, high-standard and timely scientific information. This is exactly what Open Access Journals provide and this is the reason why I support this endeavor."


Jacques Descotes
(Centre Antipoison-Centre de Pharmacovigilance, France)

"Publishing research articles is the key for future scientific progress. Open Access publishing is therefore of utmost importance for wider dissemination of information, and will help serving the best interest of the scientific community."


Patrice Talaga
(UCB S.A., Belgium)

"Open access journals are a novel concept in the medical literature. They offer accessible information to a wide variety of individuals, including physicians, medical students, clinical investigators, and the general public. They are an outstanding source of medical and scientific information."


Jeffrey M. Weinberg
(St. Luke's-Roosevelt Hospital Center, USA)

"Open access journals are extremely useful for graduate students, investigators and all other interested persons to read important scientific articles and subscribe scientific journals. Indeed, the research articles span a wide range of area and of high quality. This is specially a must for researchers belonging to institutions with limited library facility and funding to subscribe scientific journals."


Debomoy K. Lahiri
(Indiana University School of Medicine, USA)

"Open access journals represent a major break-through in publishing. They provide easy access to the latest research on a wide variety of issues. Relevant and timely articles are made available in a fraction of the time taken by more conventional publishers. Articles are of uniformly high quality and written by the world's leading authorities."


Robert Looney
(Naval Postgraduate School, USA)

"Open access journals have transformed the way scientific data is published and disseminated: particularly, whilst ensuring a high quality standard and transparency in the editorial process, they have increased the access to the scientific literature by those researchers that have limited library support or that are working on small budgets."


Richard Reithinger
(Westat, USA)

"Not only do open access journals greatly improve the access to high quality information for scientists in the developing world, it also provides extra exposure for our papers."


J. Ferwerda
(University of Oxford, UK)

"Open Access 'Chemistry' Journals allow the dissemination of knowledge at your finger tips without paying for the scientific content."


Sean L. Kitson
(Almac Sciences, Northern Ireland)

"In principle, all scientific journals should have open access, as should be science itself. Open access journals are very helpful for students, researchers and the general public including people from institutions which do not have library or cannot afford to subscribe scientific journals. The articles are high standard and cover a wide area."


Hubert Wolterbeek
(Delft University of Technology, The Netherlands)

"The widest possible diffusion of information is critical for the advancement of science. In this perspective, open access journals are instrumental in fostering researches and achievements."


Alessandro Laviano
(Sapienza - University of Rome, Italy)

"Open access journals are very useful for all scientists as they can have quick information in the different fields of science."


Philippe Hernigou
(Paris University, France)

"There are many scientists who can not afford the rather expensive subscriptions to scientific journals. Open access journals offer a good alternative for free access to good quality scientific information."


Fidel Toldrá
(Instituto de Agroquimica y Tecnologia de Alimentos, Spain)

"Open access journals have become a fundamental tool for students, researchers, patients and the general public. Many people from institutions which do not have library or cannot afford to subscribe scientific journals benefit of them on a daily basis. The articles are among the best and cover most scientific areas."


M. Bendandi
(University Clinic of Navarre, Spain)

"These journals provide researchers with a platform for rapid, open access scientific communication. The articles are of high quality and broad scope."


Peter Chiba
(University of Vienna, Austria)

"Open access journals are probably one of the most important contributions to promote and diffuse science worldwide."


Jaime Sampaio
(University of Trás-os-Montes e Alto Douro, Portugal)

"Open access journals make up a new and rather revolutionary way to scientific publication. This option opens several quite interesting possibilities to disseminate openly and freely new knowledge and even to facilitate interpersonal communication among scientists."


Eduardo A. Castro
(INIFTA, Argentina)

"Open access journals are freely available online throughout the world, for you to read, download, copy, distribute, and use. The articles published in the open access journals are high quality and cover a wide range of fields."


Kenji Hashimoto
(Chiba University, Japan)

"Open Access journals offer an innovative and efficient way of publication for academics and professionals in a wide range of disciplines. The papers published are of high quality after rigorous peer review and they are Indexed in: major international databases. I read Open Access journals to keep abreast of the recent development in my field of study."


Daniel Shek
(Chinese University of Hong Kong, Hong Kong)

"It is a modern trend for publishers to establish open access journals. Researchers, faculty members, and students will be greatly benefited by the new journals of Bentham Science Publishers Ltd. in this category."


Jih Ru Hwu
(National Central University, Taiwan)


Browse Contents




Webmaster Contact: info@benthamopen.net
Copyright © 2021 Bentham Open